Actively Recruiting
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
Led by Medical University of Vienna · Updated on 2025-09-29
1300
Participants Needed
2
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are: * What is the association between antiXa and VTE? * What is the association between antiXa and symptomatic, respectively incidental, VTE? * How is pharmacological anticoagulation with enoxaparin related to measured antiXa? * What is the association between antiXa and bleeding complications. * What is the incidence of venous thromboembolism in patients treated at an intensive care unit? * How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.
CONDITIONS
Official Title
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years at the time of intensive care unit admission
- Admission to a participating intensive care unit within the last 24 hours
- Expected discharge from the intensive care unit later than 48 hours after enrolment
You will not qualify if you...
- Receiving therapeutic anticoagulation defined as enoxaparin dose of at least 100 IE/kg twice daily or at least 150 IE/kg once daily
- Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment
- Planned regular use of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors, or factor X inhibitors during the observation period
- Estimated life expectancy below 48 hours or comfort terminal care order in place
- Previously diagnosed heparin-induced thrombocytopenia
- Pre-operative admission for elective surgery
- Previous enrolment in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Internal Medicine, Medical University of Graz
Graz, Styria, Austria, 8063
Actively Recruiting
2
Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna
Vienna, Austria, 1090
Actively Recruiting
Research Team
C
Christoph Dibiasi, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here